Description du projet
Une solution d’intelligence artificielle pour aider à prévenir les infections nosocomiales
Chaque année, près de 4,1 millions d’Européens contractent des infections pendant leur séjour à l’hôpital. Ces infections nosocomiales sont causées par des sous‑espèces bactériennes spécifiques, dont l’identification est considérablement entravée par des facteurs de temps et de coût. Pour remédier à ce problème, la société espagnole CLOVER Bioanalytical Software a utilisé l’intelligence artificielle pour développer des algorithmes et améliorer une technologie efficace appelée spectrométrie de masse à temps de vol après désorption‑ionisation laser assistée par matrice (MALDI‑TOF MS). Le projet ArtIST, financé par l’UE, permettra de découvrir, de développer et de commercialiser des solutions pour identifier rapidement et à moindre coût les processus de résistance des bactéries chez les sous‑espèces pertinentes sur le plan clinique. En outre, il réalisera une étude de faisabilité en vue de la validation clinique et de la mise sur le marché.
Objectif
Specific bacterial subspecies, often resistant to traditional antibiotics, are the cause of severe problems like Hospital-Acquired Infections and sepsis. Reducing both time and costs for identification of these subspecies, thus diagnosing more efficiently infectious diseases, is crucial for our health systems. Current solutions in the field are based on expensive and time-consuming methods, and the fast, cost-efficient existing technologies, like MALDI-TOF MS, are restricted to the identification of main bacterial species, but are unable to go down to the subspecies level. Clover Biosoft is leveraging the power of modern AI techniques to develop algorithms using MALDI-TOF MS data to successfully classify bacterial subspecies.
Ours is a collaborative project assisted by several first-level public hospitals and cutting-edge scientists from various European universities. Time-to-market is essential, and the market is ripe for our solution. MALDI-TOF MS instruments have become a standard in microbiology laboratories worldwide, allowing a very easy integration with our software. Moreover, the increasing number of patients affected by HAIs and the growing resistance to antibiotics, have raised the public concern, becoming a priority now for public and private health system managers and governments.
Clover Biosoft is the ideal player to take this solution to the market, because of our long experience in the field and our extensive network, including all relevant type of stakeholders, from hospitals to big vendor companies and from researchers to government officials. Our team has the perfect combination of technical prowess, scientific background and business acumen. Our company has obtained solid revenues from its inception. Combining public and private investment, we are confident to take this project to market and become a reference for clinical diagnosis software development, bringing wealth and work to our region.
Champ scientifique
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- natural scienceschemical sciencesanalytical chemistrymass spectrometry
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
18016 GRANADA
Espagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.